Concepedia

H. Burris

HB

Statistics

Publications

7

Citations

250

H-Index

7

Active since

2003

Affiliations

Sarah Cannon(Current)

H. Burris is an author at Sarah Cannon specializing in pharmacology, cancer pharmacology, and oncology.

Publications per year

2003–2019

7

Publications

7

First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.

H. Burris, Jordi Rodón, Shaleekha Sharma et al. · Journal of Clinical Oncology · 2010 · 109 citations

, , +10

A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors.

James D. Peyton, H. Burris, Carolyn D. Britten et al. · Journal of Clinical Oncology · 2011 · 46 citations

, , +17

Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies

Jeffrey R. Infante, Sanjay Goel, H. Burris et al. · Journal for ImmunoTherapy of Cancer · 2019 · 31 citations · Full text

, , +17

Everolimus in Combination with Exemestane for Postmenopausal Women with Advanced Breast Cancer Who Are Refractory to Letrozole or Anastrozole: Results of the BOLERO-2 Phase III Trial

J. Baselqa, Mario Campone, Tarek Sahmoud et al. · European Journal of Cancer · 2011 · 19 citations

, , +14

A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors

Andreea Varga, J.C. Soria, Antoine Hollebecque et al. · European Journal of Cancer · 2016 · 16 citations

, , +15

1–5 of 7